Medical Professional Publications

Pharmacy and Therapeutics Committee Updates

(From the October 2015 Issue of MedStat)

For more detailed information, contact Kimberly Novak at Kimberly.Novak@NationwideChildren.org.

The following actions were taken at the September 3 Pharmacy & Therapeutics Committee meeting.

The following Stock Lists were APPROVED: Allergy Clinic and Feeding Clinic Dublin.

Recommendations for antibiotic treatment of appendicitis for patients on the operative pathway were APPROVED.

A Medication use evaluation of meperidine at Nationwide Children's Hospital was presented. 130 doses were given to 78 unique patients in the previous 18 months. The most common indications were chills and/or rigors associated with administration of conventional amphotericin B, blood products, or immunologic agents and post-anesthetic shivering. Recommendation to require an indication be specified for all meperidine orders in Epic was APPROVED.

For information only - An update on adverse drug events at Nationwide Children's Hospital was provided by Dorcas Lewe.

Tocilizumab (Actemra®) was APPROVED for formulary addition. The monograph will be posted on the P&T intranet site. A review of formulary drug use will be presented in six months.

Aripiprazole extended release injectable suspension (Abilify Maintena®) was APPROVED for formulary addition restricted to Psychiatry providers only. The abbreviated monograph will be posted on the P&T intranet site. A review of formulary drug use will be presented in six months.

Haloperidol decanoate injection was APPROVED for formulary addition restricted to Psychiatry providers only. The abbreviated monograph will be posted on the P&T intranet site. A review of formulary drug use will be presented in six months.

Olanzapine pamoate extended release injectable suspension (Zyprexa Relprevv®) was DENIED for formulary addition due to the risk of post-injection delirium/sedation syndrome with associated REMS requirements.

Paliperidone palmitate injection (Invega Sustenna™) was APPROVED for formulary addition restricted to Psychiatry providers only. The abbreviated monograph will be posted on the P&T intranet site. A review of formulary drug use will be presented in six month. Of note, paliperidone palmitate injection (Invega Trinza™), which requires dosing every three months, was DENIED for formulary addition.

Risperidone extended release injection (Risperdal Consta™) was APPROVED for formulary addition restricted to Psychiatry providers only. The abbreviated monograph will be posted on the P&T intranet site. A review of formulary drug use will be presented in six months.

<< Continue reading MedStat >>

myChildren’s mobile app

iPhone and Android.

Download Today! »

Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000